These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 22245080)

  • 1. Oral biodrug delivery using cell-penetrating peptide.
    Khafagy el-S; Morishita M
    Adv Drug Deliv Rev; 2012 May; 64(6):531-9. PubMed ID: 22245080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
    Kamei N; Nielsen EJ; Khafagy el-S; Takeda-Morishita M
    Ther Deliv; 2013 Mar; 4(3):315-26. PubMed ID: 23442079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability and Limitations of Cell-Penetrating Peptides in Noncovalent Mucosal Drug or Carrier Delivery Systems.
    Kamei N; Bech Nielsen EJ; Nakakubo T; Aoyama Y; Rahbek UL; Pedersen BL; Takeda-Morishita M
    J Pharm Sci; 2016 Feb; 105(2):747-753. PubMed ID: 26869427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery.
    Kamei N; Morishita M; Ehara J; Takayama K
    J Control Release; 2008 Oct; 131(2):94-9. PubMed ID: 18692532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of the Key Factors for Optimizing the in Vivo Oral Delivery of Insulin by Using a Noncovalent Strategy with Cell-Penetrating Peptides.
    Kamei N; Shigei C; Hasegawa R; Takeda-Morishita M
    Biol Pharm Bull; 2018; 41(2):239-246. PubMed ID: 29386483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improvement of intestinal absorption of peptide and protein drugs by chemical modification with fatty acids].
    Yamamoto A
    Nihon Rinsho; 1998 Mar; 56(3):601-7. PubMed ID: 9549343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery.
    Mäe M; Langel U
    Curr Opin Pharmacol; 2006 Oct; 6(5):509-14. PubMed ID: 16860608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methodologies for regulation of intestinal absorption of biologically active peptides].
    Fujita T; Muranishi S
    Nihon Rinsho; 1998 Mar; 56(3):589-94. PubMed ID: 9549341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional matrices for oral peptide delivery.
    Bernkop-Schnürch A; Walker G
    Crit Rev Ther Drug Carrier Syst; 2001; 18(5):459-501. PubMed ID: 11763498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin.
    Nielsen EJ; Yoshida S; Kamei N; Iwamae R; Khafagy el-S; Olsen J; Rahbek UL; Pedersen BL; Takayama K; Takeda-Morishita M
    J Control Release; 2014 Sep; 189():19-24. PubMed ID: 24973720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral delivery of therapeutic proteins and peptides: a review on recent developments.
    Gupta S; Jain A; Chakraborty M; Sahni JK; Ali J; Dang S
    Drug Deliv; 2013 Aug; 20(6):237-46. PubMed ID: 23869787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models to predict intestinal absorption of therapeutic peptides and proteins.
    Antunes F; Andrade F; Ferreira D; Nielsen HM; Sarmento B
    Curr Drug Metab; 2013 Jan; 14(1):4-20. PubMed ID: 21933113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the oral route possible for peptide and protein drug delivery?
    Morishita M; Peppas NA
    Drug Discov Today; 2006 Oct; 11(19-20):905-10. PubMed ID: 16997140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral colon delivery of insulin with the aid of functional adjuvants.
    Maroni A; Zema L; Del Curto MD; Foppoli A; Gazzaniga A
    Adv Drug Deliv Rev; 2012 May; 64(6):540-56. PubMed ID: 22086142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs.
    Föger F; Kopf A; Loretz B; Albrecht K; Bernkop-Schnürch A
    Amino Acids; 2008 Jun; 35(1):233-41. PubMed ID: 17726639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
    Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
    Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium.
    Kamei N; Aoyama Y; Khafagy el-S; Henmi M; Takeda-Morishita M
    Eur J Pharm Biopharm; 2015 Aug; 94():42-51. PubMed ID: 25960330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of cell-penetrating peptides.
    Sarko D; Beijer B; Garcia Boy R; Nothelfer EM; Leotta K; Eisenhut M; Altmann A; Haberkorn U; Mier W
    Mol Pharm; 2010 Dec; 7(6):2224-31. PubMed ID: 20845937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral peptide and protein delivery: intestinal obstacles and commercial prospects.
    Smart AL; Gaisford S; Basit AW
    Expert Opin Drug Deliv; 2014 Aug; 11(8):1323-35. PubMed ID: 24816134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides.
    Kamei N; Morishita M; Takayama K
    J Control Release; 2009 Jun; 136(3):179-86. PubMed ID: 19250953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.